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In patients in whom surgery was unsuccessful or relapse 
occurred, repeat surgery, radiotherapy and bilateral adrenal-
ectomy are viable options, though associated with signifi-
cant side effects. In these cases, medical therapy represents 
an effective alternative. However, even with the advent 
of innovative therapies, as drugs directly targeting ACTH 
secretion for Cushing’s disease (CD), medical treatment of 
endogenous hypercortisolism is far from being resolving.
Recently, an Endocrine Society Clinical Practice 
Guideline for the treatment of CS has been published [2], 
the state of the art of medical therapy in CD extensively 
reviewed [3] and the use of adrenal blocking agents and 
glucocorticoid receptor blockers in hypercortisolemic 
states reappraised [4, 5]. As matters stand, “old” agents 
continue to be used in clinical practice and have been sub-
ject to a reappraisal on large series of patients in order to 
better define their pharmacological profile. According to 
their site of action, drugs for CS are classically subdivided 
into adrenal blocking agents, drugs targeting ACTH secre-
tion and glucocorticoid receptor antagonists. This review 
will define the current standing of “old” drugs in the treat-
ment of endogenous hypercortisolism.
Adrenal blocking agents
Ketoconazole
This antifungal agent has been used off-label in CS since 
the 1980s. Ketoconazole exerts its effect through interfer-
ence with enzymes involved in the conversion of choles-
terol to cortisol [6]. A further effect at hypothalamo–pitui-
tary level had been reported [7, 8] but not confirmed in later 
studies. To date, there are no prospective clinical studies 
on ketoconazole in CS and available data is drawn from 
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Introduction
Endogenous Cushing’s syndrome (CS) is a rare endocrine 
disorder caused by excess cortisol production driven by 
a pituitary or extrapituitary ACTH-secreting tumour or 
directly arising from a primary adrenal lesion. The disease 
is burdened with high morbidity and mortality [1] and thus 
prompt cure is mandatory. Surgery remains the cornerstone 
of treatment regardless of the aetiology of hypercortisolism. 
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retrospective analyses. One of the earliest series was pub-
lished in 1991 and reported a 93 % response rate in twenty-
eight patients with CD [9]. A marked reduction of urinary 
free cortisol (UFC) levels took place soon after treatment 
and persisted throughout ketoconazole administration. A 
parallel improvement, in some cases even disappearance, 
of clinical signs such as diabetes mellitus, hypertension 
and hypokalaemia, together with restoration of well-being, 
was reported. In this series, patients had been submitted to 
radiotherapy prior to ketoconazole treatment which might 
account for the brilliant results. Most recently, a French 
multicenter study reviewed data from two hundred patients 
with CD and concluded that ketoconazole represents a 
highly effective drug to control hypercortisolism [10]. In 
fact, nearly 50 % of patients achieved normalization of 
UFC (average dose 600 mg ketoconazole q.d.) and an addi-
tional 25 % displayed a decrease of UFC by at least 50 %. 
Preoperative treatment allowed improvement in signs such 
as hypertension, hypokalaemia and diabetes and thus may 
have reduced surgical risk. Secondary failure was observed 
in less than 7 % of patients but some 20 % had to inter-
rupt ketoconazole due to adverse effects, mostly hepatic 
or gastrointestinal. No fatal hepatitis was reported while 
both mild (<5-fold normal values) and major (>5-fold nor-
mal values) increases in liver enzymes occurred but proved 
transient in the great majority of patients. Of note, adrenal 
insufficiency occurred in 5 % of patients at doses rang-
ing from 400 to 1200 mg ketoconazole q.d. The results of 
the French study are quite similar to those collected in the 
English literature, showing that 60 % of treated patients 
achieved UFC normalization [4].
Ketoconazole represents the only drug approved for 
treatment of CS due to any aetiology by the European Med-
icines Agency. This recent approval will certainly lead to a 
revival in the use of this “old” drug. Of note, non-racemic 
ketoconazole, i.e., only the 2S, 4R enantiomer, is currently 
being tested in CS.
On balance, ketoconazole is a relevant tool for medical 
treatment of CS, although mostly a temporary measure. 
Treatment with ketoconazole should be individualised and 
few weeks of dose adjustment are usually necessary to con-
trol hypercortisolism. Effective dosage ranges from 200 to 
1200 mg per day and seems to be quite similar among the 
different forms of endogenous hypercortisolism. Absorp-
tion from the gastrointestinal tract is variable and enhanced 
in acidic environment [11]. Thus, its serum concentrations 
may be lower in patients with achlorhydria or on antacids, 
H2 antagonists and proton pump inhibitors. Hepatotoxic-
ity is the most common and possibly serious side effect. 
Although in most cases liver enzyme elevation is mild and 
resolves after drug withdrawal, close liver enzyme moni-
toring is necessary. Adrenal insufficiency is a rare devel-
opment. No adverse effects on electrocardiographic QT 
interval were registered after long-term administration in 
patients with CD [12]. Lastly, ketoconazole is contraindi-
cated in pregnancy since embryotoxicity and teratogenic-
ity have been reported in animal studies. Nonetheless, a 
favourable outcome has been described in a few unplanned 
pregnancies [13].
Mitotane (o,p′‑DDD)
Mitotane, also known as o,p′-DDD, is an oral cytotoxic 
agent mainly used in the management of adrenocortical car-
cinoma. In addition to its adrenolytic effect, mitotane also 
inhibits multiple steps in adrenal steroid biosynthesis and 
may possibly exert an inhibitory effect on tumorous cortico-
troph cells [14]. Unlike the other steroidogenesis inhibitors, 
mitotane displays a slow onset of action, which limits its use 
in cases of severe CS, when a prompt therapeutic response 
is required. Studies dated over 30 years ago reported clini-
cal and biochemical remission in about 80 % of patients 
with CD treated with low doses of mitotane and pituitary 
irradiation [15]. However, relapse occurred in 50–60 % of 
these patients and additional courses of drug or radiation 
therapy were necessary. A recent retrospective study on 
66 patients with CD who had not been treated with radio-
therapy reported sustained normalization of UFC in 70 % of 
patients after approximately 6 months on mitotane (median 
daily dose 2.6 g) [16]. Mitotane had to be withdrawn due 
to lack of efficacy in 15 % of patients despite halving of 
UFC levels, and in 13 % of patients due to adverse effects, 
e.g., gastrointestinal or neurologic signs. Although mito-
tane is an adrenolytic, reappearance of hypercortisolism 
occurred in some patients on average after 1 year of treat-
ment withdrawal. While plasma mitotane concentrations 
around 14–20 mg/l are needed in adrenal carcinoma, lower 
concentrations, i.e., ±8 mg/l, appear sufficient to contain 
excess cortisol secretion in patients with CD. By low daily 
doses of mitotane, it has been possible to control cortisol 
secretion for 10 years in a patient with Carney’s complex 
and Cushing’s syndrome [17]. Mitotane is approved for use 
in adrenal carcinoma, both secreting and non-secreting, and 
in severe CS in several countries. In order to establish its 
efficacy and safety, assessment of free cortisol in urine or 
serum has to be made [18] since mitotane increases plasma 
levels of hormone binding proteins, and thus cortisol bind-
ing globulin (CBG) [19], causing spurious elevations of 
total serum cortisol. Mitotane may alter the metabolism of 
synthetic steroids leading to an increased replacement need 
[20] whenever adrenal insufficiency and/or male hypog-
onadism concur. Elevations of cholesterol and triglycerides 
are also common. Dose-dependent gastrointestinal, neuro-
logical, haematological and hepatic unwanted effects may 
ensue but are usually reversible upon drug reduction or dis-
continuation. Due to the highly lipophylic structure of the 
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molecule, mitotane may remain stored in the adipose tissue 
[21] and maintain for long its effects. There are limited data 
regarding the effect of mitotane on childbearing potential 
and pregnancy outcome, thus treatment of women who are 
or who may become pregnant should be undertaken only 
after careful balance of risks and benefits.
Metyrapone
Metyrapone is used in the assessment of hypothalamic–
pituitary–adrenal function as well as in the treatment of 
CS. Its availability is however subject to country-specific 
regulations, e.g., obtainable in the UK and Italy but not 
all European countries. Metyrapone inhibits the enzyme 
responsible for the final step of cortisol biosynthesis, 
i.e., 11-beta-hydroxylase (CYP11B1) [22]. This causes 
a rapid fall in cortisol levels with accumulation of corti-
sol precursors and their entry into the synthetic pathways 
of androgens and aldosterone. For therapeutic purposes, 
metyrapone is administered orally in doses varying from 
250 mg twice or thrice daily up to a maximum of 6 g per 
day. Quite recently, a large retrospective study re-evalu-
ated 164 patients with different form of CS who received 
metyrapone monotherapy across 13 centers in UK over 
the last 25 years [23]. Overall, more than 80 % of patients 
showed an improvement in levels of circulating cortisol 
with over 50 % achieving biochemical eucortisolemia, 
i.e., early morning cortisol value of 331 nmol/l (12 μg/
dl) and mean serum cortisol day-curve of 150–300 nmol/l 
(10.9 μg/dl). Side effects, mostly mild gastrointestinal 
upset, occurred in 25 % of patients usually within 2 weeks 
of initiation or dose increase. A limitation of the study is 
represented by the measurement of serum cortisol as a 
marker of biochemical control. When UFC was used, in 
a series totalling twenty-three patients with CD not previ-
ously irradiated, metyrapone achieved biochemical con-
trol in 57 % of patients and clinical improvement in 46 % 
[24]. Escapes were recorded in three patients. Side effects 
with metyrapone are due to accumulation of androgen and 
mineralocorticoid precursors, resulting in hirsutism, acne, 
hypertension and oedema. Attention should be payed to the 
occurrence of hypocortisolism, whose laboratory diagno-
sis may be challenging due to the interference of increased 
levels of 11-deoxycortisol in the cortisol immunoassay 
[25]. Use of liquid chromatography tandem mass spectrom-
etry (LC–MS/MS) assay is therefore recommended. As 
for pregnancy, some patients with CS have been success-
fully managed with metyrapone with no teratogenic effect 
observed on the foetus [26]. However, worsening of gesta-
tional hypertension as well as development of preeclampsia 
seems to be more likely with this therapy.
LCI699 is a new inhibitor of 11-beta-hydroxylase 
(CYP11B1) and 18-hydroxylase (CYP11B2), much like 
metyrapone. In a preliminary proof-of-concept study on 
twelve patients with CD, administered at a daily dose of 
4–100 mg, LCI699 normalized UFC in eleven [27]: studies 
on larger series are under way.
Etomidate
Etomitade is a short-acting intravenous anaesthetic in use 
since the 1970s with an additional, important cortisol-
lowering effect [28]. Indeed, a low non-hypnotic dose 
of 2.5 mg/h or 0.3 mg/kg/h infused for 36 h was noted 
to cause a rapid fall of serum cortisol with a sustained 
effect until the end of the infusion [29]. Adrenal sup-
pression occurs at lower doses compared to hypnotic 
doses [30] and may persist for several days after infusion. 
Suppression of adrenal secretion, primarily by inhibi-
tion of 11-beta-hydroxylase (CYP11B1) and, to a lesser 
extent, 17-hydroxylase (CYP17A1) and 20,22 desmo-
lase (CYP11A1) [31], proved useful for rapid reversal of 
hypercortisolism as has been achieved in patients with 
severe CS, e.g., uncontained psychosis, sepsis [32]. In 
fact, a protocol for emergency management of CS has 
been recently drawn up [33]. Long-term control of hyper-
cortisolism has also been reported in individual cases, 
most notably a young woman with occult ectopic CS in 
whom etomidate was administered for over 5 months 
without significant side effects [34]. In this patient, par-
tial inhibition of steroidogenesis persisted at least 14 days 
after drug discontinuation, probably due to the lipophilic 
nature of etomidate and its storage in adipose tissue. The 
use of etomidate in severe cases of hypercortisolism has 
recently been reviewed [32].
Other adrenal blocking agents
Aminoglutethimide, an inhibitor of cholesterol side-chain 
cleavage, 11-beta-hydroxylase (CYP11B1) and 18-hydrox-
ylase (CYP11B2) [35],  and trilostane, an inhibitor of 
17-beta-hydroxysteroid dehydrogenase, 3-beta-hydrox-
ysteroid dehydrogenase (3-beta-HSD) and 17-alpha-
hydroxylase/17,20-lyase (CYP17) [36], have been used in 
the past but only occasionally in more recent times in the 
treatment of CS, because of their unsatisfactory pharmaco-
logical profile.
Drugs targeting ACTH secretion
Dopaminergic compounds: bromocriptine 
and cabergoline
Dopaminergic agents have been tested in CD and Nel-
son’s syndrome starting in the mid 1970s and again 
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in more recent years as novel agonists became avail-
able. Bromocriptine, a short-acting dopamine D2 recep-
tor (D2R) agonist, was tested first [37]. Reportedly, CD 
patients bearing a corticotroph adenomatous hyperplasia 
of the pituitary intermediate lobe, associated with argy-
rophil fibres, responded better to the dopaminergic com-
pound compared to patients with a pure corticotroph 
adenoma of the anterior portion of the gland [38]. This 
finding, with the attendant hypothesis of two different 
types of CD with different responsiveness to dopaminer-
gic drugs, could not be confirmed in subsequent studies 
[39]. In patients with CD, monthly intramuscular injec-
tion of 50 mg bromocriptine proved unable to correct the 
hypercortisolism [40], while daily oral administration of 
the drug was reported to induce clinical and biochemical 
improvement in a few patients [41, 42]. A high daily dose 
of bromocriptine, 35 mg/day or more, up to a maximum 
of 55 mg/day, was tried in six patients affected by CD 
and a favourable clinical and biochemical response was 
recorded in three of them [43]. Escape phenomena were 
registered in responsive patients [43, 44] and long-term 
control of hypercortisolism has been described only in 
a scattering of cases [45–47]. While the use of the “old” 
dopamine agonist was abandoned, dopaminergic agents 
staged a comeback with the reappraisal of cabergoline, 
the long-acting D2R agonist already in use for treatment 
of prolactin-secreting tumours. The demonstration that 
D2R are expressed in approximately 80 % of pituitary 
and ectopic ACTH-secreting tumours, with all D2R posi-
tive tumours exhibiting a significant inhibition of ACTH 
secretion when incubated with cabergoline, established 
the rationale for its trial in CD. Indeed, 8/20 (40 %) CD 
patients, all expressing D2R, exhibited a sustained nor-
malization of UFC during a 24 month treatment with up 
to 7 mg weekly cabergoline. Subsequent clinical studies 
confirmed these early observations [48]. In a prospective 
study [49], 5/18 patients with CD normalized midnight 
serum cortisol (MNSC) or low-dose dexamethasone cor-
tisol suppression (LDCS) or both, with a mean weekly 
dose of cabergoline of 3.6 mg. In four patients treated for 
1 year, sustained normalization of MNSC and LDCS took 
place in two and three of them, respectively. In the same 
year, normalization of UFC was reported in 3/12 patients 
(25 %) with CD after 6 months of cabergoline, at dosages 
up to 3 mg per week [50]. Likewise, in a retrospective 
analysis, sustained normalization of UFC was observed in 
11/30 patients (36.6 %) with cabergoline doses up to 6 mg 
per week, with nine of the responsive patients remain-
ing in persistent remission after a mean of 37 months of 
treatment. Two escapes after 2 and 5 years of a complete 
response are reported [51]. Effectiveness of cabergo-
line was recently described in two adolescent boys with 
CD who normalized their UFC after 4 and 6 months of 
treatment with 1 and 1.5 mg of cabergoline per week 
and with remission still present after 17 and 24 months 
of therapy [52]. Altogether, some eighty patients treated 
with cabergoline have been reported so far and results, 
while not brilliant, are encouraging with long-term con-
trol of hypercortisolism in around 30 % of patients, in 
some cases for several years [48–52]. Surveillance is 
recommended for the risk of cardiac valve regurgitation, 
anyhow low [53]. Novel cabergoline analogues are being 
developed aimed at improving cardiovascular safety [54].
Somatostatin analogues
Research into the therapeutic potential of somatostatin 
analogues in CS began in the 1970s and is still subject to 
intensive activity. The first studies demonstrated that soma-
tostatin itself as well as its synthetic somatostatin recep-
tor 2 agonist, i.e., octreotide, inhibited ACTH secretion in 
Nelson’s syndrome [55] and ectopic CS [56, 57]. Instead, 
octreotide was ineffective in CD [58–60], possibly a con-
sequence of down-regulation of the corticotroph somato-
statin receptor subtype 2 (SSTR2) by glucocorticoids [59, 
61]. Indeed, combined treatment with octreotide and keto-
conazole proved efficacious in three out of four patients 
with severe CD [62], but this finding was not replicated in 
subsequent studies and in five patients with CD in whom 
the pattern of ACTH and cortisol after a single s.c. admin-
istration of 100 µg octreotide was not modified by previous 
administration of 200 mg mifepristone given p.o. 12 and 
6 h before the injection [63]. Recent research attempted 
to widen the use of octreotide, that binds SSTR2, 3 and 5, 
in endogenous hypercortisolism and assessed its effect in 
patients with primary pigmented nodular adrenocortical 
disease (PPNAD), a form of ACTH-independent hypercor-
tisolism characterized by dense expression of most somato-
statin receptors in adrenal nodules. In ten patients, a single 
s.c. injection of 100 µg of octreotide failed to significantly 
modify cortisol secretion [64].
The demonstration that SSTR5 is highly expressed in 
the majority of human corticotroph adenomas and is more 
resistant to glucocorticoid down-regulation, has led to the 
development of the novel somatostatin analogues, notably 
pasireotide that binds SSTR1, 2, 3 and, with maximal affin-
ity, SSTR5 [65]. Indeed, long-term pasireotide administra-
tion halved UFC excretion in some 40 % of patients and 
normalized hormonal levels in about 20 % [66]. Untoward 
effects were those typical of somatostatin analogues, i.e., 
gastrointestinal symptoms and gallstones, except for hyper-
glycaemia-related events, which were experienced by over 
70 % of patients. In 2012 the European Medicines Agency 
has approved pasireotide (Signifor), for the treatment of 
CD in patients who have failed surgery or where surgery 
is not an option. In this context it has to be recognised that 
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if the only partial efficacy of the old drugs has stimulated 
the development of innovative compounds like pasireotide, 
the equally partial efficacy of the novel agents has renewed 
the interest for the old drugs and for a greater awareness of 
their use.
Temozolomide
Temozolomide (TMZ) is an alkylating agent developed 
30 years ago and mainly used as adjuvant treatment for 
glyomas and, to a lesser extent, malignant neuroendocrine 
tumours. It exerts its cytotoxic effects through its metabo-
lites that methylate DNA at different positions. Methylation 
at the O6 position of guanine gives rise to DNA adducts, 
leading to alterations in subsequent DNA replication and 
eventual tumorous cell apoptosis. The efficacy of the drug 
relies on the activity of the repair DNA enzyme O6-methyl-
guanine-DNA methyltransferase (MGMT) that can reverse 
alkylation. There is some experimental evidence that low 
expression of MGMT may be associated with a better 
response to TMZ [67]. Along the same line, addition of 
inhibitors of folate metabolism such as pyrimetamine or 
methotrexate appears to produce synergistic effects [68]. 
Ten years ago TMZ has been introduced for the treatment 
of aggressive pituitary tumours (adenomas and carcino-
mas). The available experience relies on anecdotal reports 
or small series of patients. However, a review of the lit-
erature clearly indicates that the drug, administered orally 
at the standard regime doses of 150–200 mg/m2/day for 
5 days every four weeks, is effective [67]. Indeed, it pro-
vides a response rate, in clinical and radiological terms, of 
around 60 % for ACTH-secreting pituitary tumours, 73 % 
for prolactinomas and 40 % for non-functioning pituitary 
tumours. Likewise, in another review of the published 
cases, TMZ has proved capable of inducing a favourable 
response in 69 % of pituitary carcinomas [69]. Finally, a 
recent Italian survey has reported on the effects of treat-
ment in thirty-one patients, twenty-five with pituitary ade-
noma and six with pituitary carcinoma. The drug was given 
orally at the initial dose of 150 mg/m2/day for 5 days every 
four weeks, with doubling of the dose from the second 
month on in the absence of severe toxic effects. Treatment, 
protracted for a maximum of 12 monthly cycles, confirmed 
its efficacy with twenty-five patients (80.6 %) showing dis-
ease control in contrast to six patients (19.4 %) exhibiting 
tumour progression. In a median follow-up of 43 months, 
the 2-year progression-free survival and the disease control 
duration were 47.7 and 59.1 %, respectively [70]. Thus, 
TMZ appears to be a viable salvage therapy for aggressive 
pituitary tumours unresponsive to the conventional treat-
ment options. Whether low expression level of MGMT 




Mifepristone, also known as RU-486, is the only drug 
currently available with anti-glucocorticoid properties. 
It is a strong competitive antagonist of type 2 glucocor-
ticoid and progesterone receptors. These effects appear 
to be dose-dependent and blockade of glucocorticoid 
receptor (GR) occurs at higher doses than those required 
to saturate progesterone receptor [73]. Of note, mifepris-
tone has a very long half-life compared with other ster-
oids and a relative binding affinity to GR 4 times higher 
than that of dexamethasone [74] and 18 times higher than 
that of cortisol [75]. Clinical efficacy of mifepristone in 
the treatment of CS was originally demonstrated in 1985 
in a patient with ectopic ACTH secretion in whom oral 
drug administration at increasing doses up to 20 mg/kg 
reversed clinical features of hypercortisolism [76]. More 
recently, an open-label prospective trial was carried 
out in fifty patients with refractory CS of various aeti-
ologies, mainly pituitary-dependent CS (86 %) [77]. A 
starting dose of 300 mg/day was increased step-wise up 
to 1200 mg/day depending on clinical efficacy. Amelio-
ration of diabetes mellitus and diastolic blood pressure, 
i.e., the two primary endpoints of the study, was observed 
in 60 and 38 % of patients, respectively. Moreover, a post 
hoc analysis of secondary endpoints including glucose 
homeostasis, blood pressure, lipid control, weight and 
body composition, physical appearance, strength, neu-
ropsychological status and quality of life also revealed an 
overall progressive clinical benefit of treatment in 88 % 
of patients [78] with no significant association between 
dose escalation and increase of adverse effects [79]. 
Although poorly understood, a gender-related difference 
in drug effectiveness, i.e., a faster response to treatment 
in males, seemed to be present. Administration of mife-
pristone has also proved helpful in selected paediatric 
patients [80].
In 2012 the U.S. Food and Drug Administration has 
approved the use of mifepristone in patients with endoge-
nous CS and type 2 diabetes mellitus or glucose intolerance 
who were not candidates for or did not benefit from prior 
surgery. Long-term data on the efficacy and safety of mife-
pristone in CS are not yet available.
Adrenal insufficiency, albeit uncommon, and hypoka-
laemia have been reported as major severe drawbacks of 
mifepristone use [77]. Since serum cortisol levels remain 
elevated and may even increase during treatment [81], 
there are no reliable markers both to monitor the bio-
chemical response and avoid acute adrenal failure. The 
latter occurrence should be carefully watched since it may 
not be easily reversible by glucocorticoid administration. 
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Indeed, protracted administration of glucocorticoids after 
mifepristone withdrawal is necessary to overcome its GR 
blocking effect [82]. Furthermore, increased cortisol lev-
els can lead to severe hypokalaemia and/or hypertension 
due to the over-activation of mineralocorticoid receptors 
[83]. In addition, female patients receiving mifepristone 
may present vaginal bleedings due to endometrial thicken-
ing caused by the anti-progestinic effects of the drug [77]. 
Lastly, caution should be exercised when mifepristone is 
administered with drugs that are CYP3A or CYP2C sub-
strates, such as simvastatin, cyclosporine, fentanyl, cipro-
floxacin, non-steroidal anti-inflammatory drugs and war-
farin, since drug-related toxicity might occur. Altogether, 
also due to its rapid onset of action, mifepristone may be 
particularly useful in acute hypercortisolemic crises asso-
ciated with severe clinical manifestation as psychosis.
Combination treatments
Combined administration of the compounds mentioned 
above can help to enhance and hasten the effects of treat-
ment in cases of severe hypercortisolism and to reduce the 
dosage of the single agents so as to improve their toler-
ability. In this context, addition of ketoconazole enabled 
UFC normalization in 6/9 CD patients not fully respon-
sive to cabergoline [50]. This sequence of drug adminis-
tration has been questioned by other investigators who, 
in a small series, obtained comparable results using the 
reverse combination, i.e., adding cabergoline to keto-
conazole [84]. Likewise, simultaneous administration of 
mitotane, metyrapone and ketoconazole in eleven patients 
with ACTH-dependent CS led to rapid and sustained fall 
of UFC levels, which made possible a successful “rescue 
adrenalectomy” in five of them [85]. Along the same line, 
administration of pasireotide with stepwise addition of 
cabergoline and ketoconazole when a complete response 
was not achieved, led to UFC normalization in 15/17 
patients with CD [86]. Finally, combination treatment with 
metyrapone and ketoconazole has proved capable of nor-
malizing UFC in 10/14 patients with ectopic ACTH secre-
tion and in 6/8 patients with adrenocortical carcinoma 
[87].
Conclusion
Since the first description by Harvey Cushing in 1932 
[88] significant advances have been made in the manage-
ment of endogenous hypercortisolism. While pituitary 
surgery remains the first-line therapy, medical treatment 
for patients not attaining remission or experiencing recur-
rence still largely rests on agents which have been first 
tested decades ago. Some of them, like ketoconazole, 
have never been abandoned from their initial use while 
others like metyrapone, cabergoline and mifepristone 
have undergone a recent reappraisal. Until compounds 
capable of satisfactorily containing the ACTH secretion 
will be developed, the “old” drugs described above will 
be of help in the management of these patients (Table 1). 
Authorization for use in CS in Europe or the US has 
finally sanctioned the importance of “old” drugs or their 
derivatives, thereby underscoring their usefulness after 
years of off-label use.
Table 1  “Old” pharmacological agents still used for the treatment of Cushing’s syndrome
Drug Dose Main adverse events
Adrenal blocking agents
Ketoconazole 400–1600 mg/day Reversible liver toxicity, gastrointestinal discomfort, gynaecomastia, hypog-
onadism in men
Mitotane 500 mg/day to 6 g/day Gastrointestinal discomfort, liver toxicity, impaired concentration and dizzi-
ness, gynaecomastia, cholestasis, hyperlipidemia, prolongation of bleeding 
time
Metyrapone 500 mg/day to 4 g/day Hirsutism, acne, hypertension, oedema, gastrointestinal discomfort, dizziness
Etomidate Bolus of 0.03 mg/kg followed by infusion of 
0.1 mg/kg/h
Sedation, nephrotoxicity
Drugs targeting ACTH secretion
Cabergoline 1–7 mg/week Nausea, postural hypotension, headache, cardiac valvular regurgitation (high 
doses)
Temozolomide 150–200 mg/m2/day for 5 days every four weeks Myelotoxicity, nausea/vomiting, fatigue
Glucocorticoid receptor antagonists
Mifepristone 300–1200 mg/day Hypokalemia, worsening of hypertension, endometrial hyperplasia and gas-
trointestinal discomfort, adrenal function assessment precluded
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